Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2018-10, Vol.32 (10), p.2288-2291
Hauptverfasser:	Eadie, Laura N, Hughes, Timothy P, White, Deborah L
Format:	Artikel
Sprache:	eng
Schlagworte:	38/77 631/67/1990/283/1896 692/499 Antineoplastic Agents - therapeutic use ATP Binding Cassette Transporter, Subfamily B - metabolism Brief Communication Cancer Research Critical Care Medicine Enzyme inhibitors Hematology Humans Imatinib Mesylate - therapeutic use Intensive Internal Medicine Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism Medicine Medicine & Public Health Oct-1 protein Octamer Transcription Factor-1 - metabolism Oncology Prazosin - therapeutic use Protein Kinase Inhibitors - therapeutic use Protein-Tyrosine Kinases - metabolism Pyrimidines - therapeutic use RNA, Messenger - metabolism Tyrosine Tyrosine kinase inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!